Reexamination has quietly become one of the sharpest tools in patent strategy: a way to test a patent's validity, or someone else's, without the cost of litigation. More firms are using it in business development conversations. More corporate IP teams are using it to size up risk before they rely on a patent or assert one. But the data behind those decisions has always lived somewhere hard to reach: buried in USPTO records, disconnected from the original prosecution history that actually explains why a patent held up or didn't.
Juristat is closing the gap. This data is now live in the Juristat platform for subscriptions that include Reexam.
This question comes up constantly, before a licensing deal, before an assertion, before a client bets a product line on a piece of IP. Right now, most people answer it with intuition, a lawyer's read on the claims, or a manual pull of whatever reexam records they can find. None of that connects back to why: what the original prosecution looked like, how many office actions it took to issue, what rejections it survived the first time.
Juristat connects both sides. Every reexam involves two applications, the challenge itself and the original patent under review, and until now, no one has made it easy to see them together at scale. That connection is the whole point: it's what lets you ask whether a patent that sailed through prosecution on the first office action holds up differently than one that fought through five. It's what turns a single reexam into a benchmark against every other reexam in that art unit, examiner, or technology class.
It also means you're not walking in blind on timing. Based on similar reexams — same art unit, same examiner, same technology class — Juristat can anticipate how long each stage is likely to take, from filing through determination, NIRC, certificate, and disposition. So instead of telling a client "reexams take a while," you can tell them what to expect at each stage, grounded in how comparable proceedings actually played out.
For firms, this is a business development lever as much as it's a research tool. Walking into a pitch with a data-backed read on how a prospect's competitors' patents have fared under challenge (or how the prospect's own portfolio would likely hold up) is a different conversation than a general capabilities pitch. It signals depth that's hard to fake, and it gives you something concrete to open with: here's where your exposure actually is, and here's the data to back it up.
It's also a credibility play with existing clients. When you can tell them not just what happened to their patent, but how that outcome compares to hundreds of similar proceedings. You're not just reporting results; you're advising.
For corporate IP teams, reexam data is portfolio management applied to a risk that's usually invisible until it's too late. Most portfolio strategy is built around issuance data and litigation exposure. Reexam fills the gap in between: it tells you which of your patents (or a competitor's) have already been tested, what survived, and what that predicts about the rest of the portfolio sitting untested.
That reframes reexam from a reactive, case-by-case cost center into something you can watch proactively, or a way to see where you or your competitors are exposed before a challenge happens, not after.
The value here isn't just having reexam data; it's having it connected to full prosecution history, benchmarked across tech centers, art units, and examiners, and reachable from wherever you're already working, whether that's a filterable dashboard, an AI drafting conversation, or your own internal tools. That combination of reexam outcomes tied to the prosecution that produced them, at this level of depth, isn't something the market has had access to before.
Reach out to your Juristat representative to talk through what this looks like for your firm or your portfolio, or sign up to see it live with your data here.